Assessment of just HC and TP53 mutation status constitutes a relatively simple means of identifying the roughly 20% of CK-MDS patients predicted to have an OS that resembles that of IPSS-R intermediate risk patients. This evidence concerns the gene TP53 and myelodysplastic syndrome.